
ARase Therapeutics
Geography: Boston
Indication: HRD-high tumors in breast, ovarian, pancreatic, lung, and prostate cancers
Leadership: Paul Chang
ARase is developing first-in-class therapeutics targeting ADP-ribose hydrolases, a novel approach to disrupting key cancer stress pathways. By leveraging small molecules to exploit tumors with deficient DNA repair mechanisms, ARase aims to create precision oncology treatments for cancers that lack effective therapeutic options.
Visit Site
© 2026 Portal Innovations LLC
Capital. Space. Expertise.
